

**HEALTH TECHNOLOGY APPRAISAL: NICE Health Technology Appraisal -**

**Bavacizumab, sorafenib, sunitinib (second line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma**

**Appraisal Consultation Document – February 2009**

**TO: NICE**

**FROM: NHS Quality Improvement  
Scotland**

1. Whether you consider that all the relevant evidence has been taken into account.

**Yes**

2. Whether you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence.

**Yes**

3. Whether you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS.

**No-there are currently a significant number of kidney cancer patients receiving interferon therapy as this is the only active treatment available,these patients should be allowed to switch to sunitinib if they develop progression**

  
04 March 2009